KYMERA THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Gorjan Hrustanovic, Ph.D.

KYMERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Gorjan Hrustanovic, Ph.D.”): 48,998,105 for, 6,809,196 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 16,166,074 for, 3,303,243 withheld, 29,852 abstained.

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

Description as filed by funds: To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Pamela Esposito, Ph.D.

KYMERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Pamela Esposito, Ph.D.”): 49,219,482 for, 6,587,819 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 16,167,644 for, 3,301,673 withheld, 29,852 abstained.

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

Description as filed by funds: To elect three class I directors to our Board of Directors, to serve until the 2027 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Victor Sandor, M.D.C.M.

KYMERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Victor Sandor, M.D.C.M.”): 51,424,753 for, 4,382,548 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 17,123,050 for, 2,367,250 withheld, 8,869 abstained.

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

Description as filed by funds: TO APPROVE AN AMENDMENT TO THE KYMERA THERAPEUTICS, INC. 2020 STOCK OPTION AND INCENTIVE PLAN.

KYMERA THERAPEUTICS INC.’s own tally for this item (“4. Approval of Amendment No”): 30,565,165 for, 25,232,934 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4 – Approval of Amendment No. 1 to the Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan The shareholders of the Company approved the amendment to the Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan to amend the evergreen provision to provide that any of the Com…”
Support: 54.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 69 asset managers below reported 2,919,019 for, 16,575,774 against, 4,376 abstained.

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers;

KYMERA THERAPEUTICS INC.’s own tally for this item (“2. Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers”): 54,201,734 for, 1,599,511 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers The shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 69 managers: 19,071,765 for, 456,735 against, 1,184 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 134 managers: 52,883,363 for, 1,346,566 against. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; and

KYMERA THERAPEUTICS INC.’s own tally for this item (“3. Ratification of Appointment of the Company's Independent Registered Public Accounting Firm”): 57,657,124 for, 4,271 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The shareholders of the Company ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 69 asset managers below reported 19,528,500 for, 1,184 abstained.

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.